Monograph Details
|
|
Hematology
> Thromboembolic disorders
|
|
THROMBATE III |
| Manufacturer |
|
Talecris Biotherapeutics, Inc. |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Thrombin inhibitor (α2-glycoprotein). |
| Generic Name |
|
Antithrombin III (human) 500 IU, 1000 IU; per vial; lyophilized pwd for IV infusion after reconstitution; preservative-free. |
| Indications |
|
Treatment of patients with hereditary antithrombin III deficiency (AT-III) in surgical or obstetrical procedures and thromboembolism. |
| Children |
|
Not recommended. |
| Adults |
|
Give by IV infusion over 10–20 minutes. Individualized. Dose (units required)= [desired (% of normal) – baseline (% of normal) AT-III level] X weight (kg)/1.4. Loading dose: increase AT-III to 120% of normal. Subsequent dose should be based on AT-III levels obtained 20 minutes post-infusion, every 12hrs, and before the next dose. Maintain AT-III levels at 80–120% of normal for 2–8 days. |
| Precautions |
|
Surgery. Hemorrhage. Acute thrombosis. Monitor AT-III levels during treatment. Contains human plasma; monitor for possible infection transmission. Pregnancy (Cat.B). |
| Interactions |
|
Potentiates anticoagulant effect of heparin; reduce heparin dose. |
| Adverse Reactions |
|
Dizziness, chest tightness, nausea, taste disturbances, chills, cramps, shortness of breath, chest pain, light-headedness, bowel fullness, hives, fever, hematoma formation. |
| Extra Text |
|
Note: Report all infections suspected to be transmitted by Thrombate III to (800) 520-2807. |
| How Supplied |
|
Single-use vial—1 (w. diluent, needles) |
|
|
|
|
